- /
- Supported exchanges
- / US
- / BCTX.NASDAQ
Briacell Therapeutics Corp (BCTX NASDAQ) stock market data APIs
Briacell Therapeutics Corp Financial Data Overview
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Briacell Therapeutics Corp data using free add-ons & libraries
Get Briacell Therapeutics Corp Fundamental Data
Briacell Therapeutics Corp Fundamental data includes:
- Net Revenue:
- EBITDA: -30 268 288
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Briacell Therapeutics Corp News
New
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechn...
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to dateBria-IMT regi...
Big Bank Earnings, Inflation Data in Focus as US Equity Futures Slip Pre-Bell
US equity futures were down ahead of Wednesday's opening bell as traders digested more bank earnings PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering
(RTTNews) - BriaCell Therapeutics Corp. (BCTX, BCTXL), a clinical-stage biotechnology company, on Wednesday announced the pricing of a public offering of 5.367 million units at $5.59 per unit, for gro...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.